Page 1 | Search Results | Blood | American Society of Hematology

1-5 of 5

Sort by

Sort Order Select

Journal Articles

Minimal Residual Disease (MRD) Status Following Induction Chemo-Immunotherapy Predicts Progression-Free Survival In Mantle Cell Lymphoma (MCL): CALGB 50403 (Alliance)

Noreen Fulton, B.S., Jeffrey Johnson, M.S., Lawrence D. Kaplan, M.D., Greg Koval, B.S., Greg Malnassy, B.S., Sin-Ho Jung, Ph.D., Steve Devine, M.D., Thomas C. Shea, M.D., John P. Leonard, M.D., Bruce D. Cheson, M.D., Wendy Stock, M.D.

Blood (2013) 122 (21): 3002.

https://doi.org/10.1182/blood.V122.21.3002.3002

Published: 2013

Journal Articles

Salvage Therapy with Bortezomib Plus Lenalidomide for Relapsed/Refractory Mantle Cell Lymphoma: Initial Results of a Phase II Trial (Alliance/CALGB 50501)

Vicki A. Morrison, MD, Sin-Ho Jung, PhD, Jeffrey Johnson, MS, Ann LaCasce, MD, Kristie A. Blum, MD, Nancy L. Bartlett, MD, Bruce D. Cheson, MD

Blood (2012) 120 (21): 3696.

https://doi.org/10.1182/blood.V120.21.3696.3696

Published: 2012

Journal Articles

Daunorubicin Dose Intensification during Treatment of Adult Acute Lymphoblastic Leukemia (ALL): Final Results from Cancer and Leukemia Group B Study 19802.

Wendy Stock, MD, Jeffrey Johnson, MS, Daohai Yu, PhD, Diane Bennett, BSN, Dorie Sher, BS, Richard M. Stone, MD, Jonathan E. Kolitz, MD, Bayard L. Powell, MD, Meir Wetzler, MD, James W. Vardiman, MD, Clara D. Bloomfield, MD, Richard A. Larson, MD

Blood (2005) 106 (11): 1833.

https://doi.org/10.1182/blood.V106.11.1833.1833

Published: 2005

Journal Articles

Phase II Study of Thalidomide in Escalating Doses for Follicular (F-NHL) and Small Lymphocytic Lymphoma (Sll): CALGB Study 50002.

David L. Grinblatt, M.D., Jeffrey Johnson, Donna Niedzwicki, Ph.D., David A. Rizzieri, M.D., Nancy Bartlett, M.D., Bruce D. Cheson, M.D.

Blood (2004) 104 (11): 3284.

https://doi.org/10.1182/blood.V104.11.3284.3284

Published: 2004

Journal Articles

Eradication of Minimal Residual Disease during Treatment of Mantle Cell Lymphoma: CALGB 59909.

Dorie Sher, BS, Jeffrey Johnson, PhD, Mariah Siddiqui, Michael A. Caligiuri, MD, Lloyd E. Damon, MD, George P. Canellos, MD, Charles Linker, MD, Bruce D. Cheson, MD, Wendy Stock, MD

Blood (2004) 104 (11): 1652.

https://doi.org/10.1182/blood.V104.11.1652.1652

Published: 2004

NARROW

Minimal Residual Disease (MRD) Status Following Induction Chemo-Immunotherapy Predicts Progression-Free Survival In Mantle Cell Lymphoma (MCL): CALGB 50403 (Alliance)

Salvage Therapy with Bortezomib Plus Lenalidomide for Relapsed/Refractory Mantle Cell Lymphoma: Initial Results of a Phase II Trial (Alliance/CALGB 50501)

Daunorubicin Dose Intensification during Treatment of Adult Acute Lymphoblastic Leukemia (ALL): Final Results from Cancer and Leukemia Group B Study 19802.

Phase II Study of Thalidomide in Escalating Doses for Follicular (F-NHL) and Small Lymphocytic Lymphoma (Sll): CALGB Study 50002.

Eradication of Minimal Residual Disease during Treatment of Mantle Cell Lymphoma: CALGB 59909.

Email alerts

ASH Publications

American Society of Hematology

Minimal Residual Disease (MRD) Status Following Induction Chemo-Immunotherapy Predicts Progression-Free Survival In Mantle Cell Lymphoma (MCL): CALGB 50403 (Alliance)

Salvage Therapy with Bortezomib Plus Lenalidomide for Relapsed/Refractory Mantle Cell Lymphoma: Initial Results of a Phase II Trial (Alliance/CALGB 50501)

Daunorubicin Dose Intensification during Treatment of Adult Acute Lymphoblastic Leukemia (ALL): Final Results from Cancer and Leukemia Group B Study 19802.

Phase II Study of Thalidomide in Escalating Doses for Follicular (F-NHL) and Small Lymphocytic Lymphoma (Sll): CALGB Study 50002.

Eradication of Minimal Residual Disease during Treatment of Mantle Cell Lymphoma: CALGB 59909.

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only